OGN News and Press, Organon & Co. From 03/02/22

Shares of Organon & Co. (NYSE:OGN) traded today at $38.28, eclipsing its 52-week high. So far today approximately 390,000 shares have been exchanged, as compared to an average 30-day volume of 2.2 million shares. Organon & Co is a science-based global pharmaceutical company that ...

Organon (NYSE: OGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fireside chat at the Cowen 42 nd Annual Healthcare Virtual Conference on Wednesday, March 9, 2022 at 9:10 a.m. EST. Investo...

Organon (NYSE: OGN), a global women’s health company, today announced the appointment of Meghan Rivera as US Managing Director. With over 20 years of commercial experience in bio-pharmaceutical organizations and digital therapeutics, Ms. Rivera will be responsible for leading Org...

Viatris was formed by the merger of Pfizer's Legacy Brands business Upjohn with generic drug developer Mylan. Organon was formed after Merck spun out its Women's Health, biosimilars and legacy brands division to form a separate company. Both companies are strikingly undervalued ba...

Organon & Co. (OGN) Q4 2021 Results Conference Call February 17, 2022 08:30 AM ET Company Participants Jennifer Halchak - VP, IR Kevin Ali - CEO Matt Walsh - CFO Conference Call Participants Jason Gerberry - Bank of America Chris Schott - JP Morgan Greg Fraser - Truist Securities Umer Raf...

The following slide deck was published by Organon & Co. in conjunction with their 2022 Q4 earnings call. For further details see: Organon & Co. 2022 Q4 - Results - Earnings Call Presentation

Organon (NYSE:OGN) set its 2022 revenue in line with Wall Street forecasts even as the contraction in its topline and the bottom line continued for another quarter in Q4 2021. The revenue for the quarter dropped ~1% YoY to $1.6B as Established Brands generated $1.0B in revenue with a ~2% YoY ...

Organon press release (NYSE:OGN): Q4 Non-GAAP EPS of $1.37 beats by $0.10. Revenue of $1.6B (-0.6% Y/Y) beats by $20M. FY22 Guidance: Revenue of $6.1-$6.4B vs. $6.34B consensus. Adj. gross margin of mid 60%. SG&A as % of sales mid 20% R&D as % of sales mid to upper single digit. Adjus...

Nexplanon ® (etonogestrel implant), fertility, biosimilars grew double digits for full year Full year 2021 revenue of $6.3 billion Income from continuing operations before tax of $1.5 billion for full year 2021 Full year Adjusted EBITDA of $2.4 billion...

Organon (NYSE:OGN) is scheduled to announce Q4 earnings results on Thursday, February 17th, before market open. The consensus EPS Estimate is $1.27 and the consensus Revenue Estimate is $1.58B. Over the last 3 months, EPS estimates have seen 2 upward revisions and 3 downward. Revenue estimate...